To date, the application of the cause-specific framework is the standard practice in safety analyses. Here we analyze how the safety analysis results of new medications would be affected if instead of the cause-specific the subdistribution framework was chosen. We conducted a simulation study with...
New, better medications are the best and swiftest way for this country to cut down on our health care expenses. And appropriate reimbursement stimulates competition – which drives down prices. When it comes to measuring value, we must embrace a comprehensive view of cost and benefit. Choosing ...
It is essential to investigate the potential synergy between a new drug and existing medications approved by the US FDA. This approach could even be extended to situations where adjuvant treatment, such as tau-related treatments, is provided after amyloid clearance has been achieved. Clinical trials...
Aimovig (erenumab-aooe) May 17, 2018 Amgen Inc. calcitonin gene-related peptide antagonist subcutaneous injection once monthly For more information, see Treatment & Prevention Tips for Living with Migraine Headaches For a complete list of migraine treatments, see Medications for MigraineRead...
intranasally administered CGRP receptor antagonist that is approved for the acute, but not for the prophylactic treatment, of migraine (Dhillon2023c; Larik et al.2023). Intranasal zavegepant may benefit patients with migraine for whom oral medications are ineffective, slow-acting, or intolerable due...
Medication sharing, storage, and disposal practices for opioid medications among US adults. JAMA Intern Med. 2016;176(7):1027-1029. doi:10.1001/jamainternmed.2016.2543ArticlePubMedGoogle ScholarCrossref 26. Lamvu G, Feranec J, Blanton E. Perioperative pain management: an update for obstetrician...
It will require the manufacturers to provide educational material to prescribers and patients on the safe use of these pain medications. The FDA is establishing goals to assess and audit this training. According to the FDA, the first educational activities will be offered to prescribers by March...
treatmenthas come a long way. With daily medication, most people with HIV can live a normal life span. But unmet needs still remain. Some people, for example, find it hard to remember to take their medicine every day. Others develop drug-resistant strains of HIV that make medications ...
the participants are eligible to enter a 48-week open-label extension period, in which they are to receive bepranemab treatment for 44 weeks. Subsequently, they are to participate in a safety evaluation visit 20 weeks after the last infusion. The primary outcome measure is the CDR-SB score...
combined with subsequent optimization of leads through modern medicinal chemistry, followed by toxicology and metabolic studies and an understanding of basic pharmacokinetics, would lead to a range of new and more effective medications for those who did not respond well to the original antipsychotics, ...